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Abstract
Background Pediatric drug development is hampered by
practical, ethical, and scientific challenges. Microdosing is
a promising new method to obtain pharmacokinetic data in
children with minimal burden and minimal risk. The use of
a labeled oral microdose offers the added benefit to study
intestinal and hepatic drug disposition in children already
receiving an intravenous therapeutic drug dose for clinical
reasons.
Objective The objective of this study was to present pilot
data of an oral [14C]paracetamol [acetaminophen (AAP)]
microdosing study as proof of concept to study develop-
mental pharmacokinetics in children.
Methods In an open-label microdose pharmacokinetic
pilot study, infants (0–6 years of age) received a single oral
[14C]AAP microdose (3.3 ng/kg, 60 Bq/kg) in addition to
intravenous therapeutic doses of AAP (15 mg/kg
intravenous every 6 h). Blood samples were taken from an
indwelling catheter. AAP blood concentrations were mea-
sured by liquid chromatography–tandem mass spectrome-
try (LC-MS/MS) and [14C]AAP and metabolites
([14C]AAP-Glu and [14C]AAP-4Sul) were measured by
accelerator mass spectrometry.
Results Ten infants (aged 0.1–83.1 months) were inclu-
ded; one was excluded as he vomited shortly after
administration. In nine patients, [14C]AAP and metabolites
in blood samples were detectable at expected concentra-
tions: median (range) maximum concentration (Cmax)
[14C]AAP 1.68 (0.75–4.76) ng/L, [14C]AAP-Glu 0.88
(0.34–1.55) ng/L, and [14C]AAP-4Sul 0.81 (0.29–2.10) ng/L.
Dose-normalized oral [14C]AAP Cmax approached median
intravenous average concentrations (Cav): 8.41 mg/L
(3.75–23.78 mg/L) and 8.87 mg/L (3.45–12.9 mg/L),
respectively.
Conclusions We demonstrate the feasibility of using a
[14C]labeled microdose to study AAP pharmacokinetics,
including metabolite disposition, in young children.
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Key Points
A [14C]labeled microdosing study is feasible in
young children.
[14C]Labeled microdosing may be used to study
developmental pharmacokinetics, including oral
bioavailability.
1 Introduction
Up to 70 % of drugs prescribed to children are unlicensed
or off-label, which brings risk of drug toxicity or thera-
peutic failure [1, 2]. However, pediatric drug studies face
important ethical, practical, and scientific challenges [3]. A
major challenge—against the background of developmen-
tal changes in drug absorption, distribution, metabolism,
and excretion—is appropriate dose selection [4]. Simple
size- or weight-based extrapolations from adult to pediatric
doses do not suffice, particularly in neonates and infants.
Current strategies include simulations using population
pharmacokinetic (popPK) and physiologically based phar-
macokinetic (PBPK) models [5–9]. The usefulness of these
models may be limited, as relatively little pediatric phar-
macokinetic and physiological data are available to vali-
date them. Hence, new data are needed to support these
models, as well as alternative methods to collect pharma-
cokinetic data without the inherent risks of toxicity when a
therapeutic dose is given for the first time in a specific age
group.
Microdosing is an interesting alternative. The European
Medicines Agency (EMA) and the US Food and Drug
Administration (FDA) define a microdose as one-hun-
dredth of the No Observed Adverse Effect Level (NOAEL)
or predicted pharmacologic dose based on animal data or as
100 lg of the new drug, whichever dose is lower [10, 11].
Dose linearity between the microdose and therapeutic dose
is a prerequisite to extrapolate pharmacokinetic data to
dosing guidelines [12]. The extremely low dose concen-
trations call for highly sensitive measurements. Accelerator
mass spectrometry (AMS) can measure low attomolar to
zeptomolar isotope ratio ranges, to quantify [14C]labeled
drug or metabolite concentrations in urine or plasma
samples, even after at least five half-lives following a
microdose [13]. [14C] Labeling of a microdose is associ-
ated with very low radiation exposure, i.e., less than
10 lSv in adults, when compared with the yearly back-
ground exposure of 2.5 mSv/year in The Netherlands [14].
Hence, microdosing is safe to use to study pharmacoki-
netics in children. In clinical care, [14C]urea has been
safely used to test for Helicobacter pylori infection [15]. A
[14C]ursodiol microdose study in preterm infants was
briefly described in an excellent review on the potential for
use of AMS in children [16]. Administering a labeled oral
microdose to children already receiving a therapeutic drug
dose for clinical reasons intravenously offers the added
possibility to study oral bioavailability [12, 17]. This
approach may also serve to delineate developmental
changes in the drug-metabolizing enzymes involved in
intestinal and hepatic drug metabolism [17, 18].
Paracetamol (acetaminophen; AAP), is much used in
children and is an interesting study drug for several rea-
sons. First, its metabolism shifts from primarily sulphation
(AAP-sulphate [AAP-Sul]) to glucuronidation (AAP-glu-
curonide [AAP-Glu]) in the first year of life, as reflected by
urinary metabolite kinetics [19, 20]. The relative contri-
bution of intestinal and hepatic drug metabolism has not
been studied to date. Second, dose linearity under normal
conditions and after probenecid glucuronidation inhibition
was shown in adults [18]. We therefore selected oral
[14C]AAP to study the developmental changes in AAP
glucuronidation and sulphation in children already receiv-
ing the non-labeled or ‘cold’ drug intravenously for anal-
gesia [14]. This paper presents our first pilot data as proof
of concept of this promising, safe method to study devel-
opmental pharmacokinetics in children.
2 Methods
2.1 Study Design
This proof-of-concept study is part of a larger pheno-
typing study in 60 children delineating developmental
changes in AAP to metabolite clearance (EudraCT
2011-005497-28). The Dutch Central Committee on
Research Involving Human Subjects (The Hague, The
Netherlands) approved the larger study. Parents or legal
guardians gave informed consent. Radiation exposure
was explained during the informed consent procedure
in relation to background exposure and exposure from
medical imaging. The Dutch Nuclear Research and
Service Group estimated individual exposures at
approximately 1 lSv for a 0- to 2-year-old child, well
below the minimal risk category 1 (100 lSv) of the
International Commission of Radiological Protection
and the yearly background exposure (2.5 mSv). Cate-
gory 1 risk studies are considered minimal risk and are
allowed when they provide new scientific knowledge
[11].
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2.2 Subjects
Patients admitted to the Intensive Care department of the
Erasmus MC-Sophia Children’s Hospital (Rotterdam, The
Netherlands) were considered for inclusion. Inclusion cri-
teria were age between 0 and 6 years, gestational age
[36 weeks, medical need for intravenous AAP, and an
indwelling central venous or arterial line in place. To
reduce pharmacokinetic variability due to underlying dis-
ease, patients with kidney and liver injury or the use of
more than one vasopressor drug were excluded, as well as
children intolerant to enteral nutrition.
2.3 Study Procedures
A single oral [14C]AAP microdose (3.3 ng/kg, 60 Bq/kg,
0.25 mL/kg) followed by 1 mL of saline (to ensure rinsing
of the enteral feeding tube) was administered in addition to
the intravenous therapeutic dose of AAP (15 mg/kg intra-
venously every 6 h) prescribed by the treating physician to
provide analgesia. The [14C]AAP oral dose also contained
1.7 lg/kg non-labeled AAP, but this amount was negligible
in relation to the therapeutic intravenous dose and thus
considered irrelevant for the pharmacokinetic estimations.
The microdose was based on a previous adult [14C]AAP
microdose study using 100 lg/7.1 kBq/individual and was
normalized for weight [21]. Blood samples (0.5 mL) were
taken from the indwelling catheter before and at
10–30 min, 1, 2, 4, 6, 12, and 24 h after dosing. Blood
samples were centrifuged and plasma was stored at -80 C
until analysis.
2.4 Medicinal Products
The AAP formulation (10 mg/mL) was purchased from
Fresenius Kabi, Schelle, Belgium. [14C]AAP was pur-
chased from Moravek Biochemicals (Brea, CA, USA).
2.5 Radiopharmaceutical Preparation
The formulation for oral administration [14C]AAP was
prepared by adding [14C]AAP to an AAP formulation for
intravenous use at the good manufacturing practice (GMP)
radiopharmaceutical production laboratories of the
Department of Radiology and Nuclear Medicine at the VU
University Medical Center (Amsterdam, The Netherlands)
(GMP license no. NL/H 11/0005) at final concentrations of
13 ng/mL for [14C]AAP and 6.7 lg/mL for non-labeled
AAP. The mixed formulation was passed over a Millex-
GV 0.22 lm filter and dispended in 20 mL sterile vials.
Radiochemical purity was[99 %; chemical purity[98 %.
The radiopharmaceutical was heat sterilized and was
shown to be stable for 2 months.
Non-specific binding was tested by running the
[14C]AAP formulation followed by 1 mL of saline through
enteral feeding tubes. Radioactive recovery measured by
liquid scintillation was greater than 95 %.
2.6 Paracetamol (Acetaminophen; AAP) Analysis
AAP concentrations were measured in the Hospital Phar-
macy laboratory of Erasmus MC with a clinically used
enzyme multiplied immunoassay technique (EMIT, Abbott
Laboratories, Weesp, the Netherlands) immunoassay
method (Abbott Laboratories) with a lower limit of
quantification (LLOQ) of 2.8 mg/L.
2.7 [14C]AAP and Metabolite Analysis
2.7.1 Plasma Sample Extraction and Ultra Performance
Liquid Chromatography Separation
Using 175 lL 100 % v/v methanol containing 6.6 lg/mL
of AAP in 96-well protein precipitation plates, 45 lL of
plasma was extracted. The pellet was washed with 100 lL
0.9 % NaCl :100 % methanol (1:4 v/v). Resulting filtrates
were evaporated to dryness, and re-dissolved in 30 lL
10 mM ammonium phosphate pH3.4 (Eluent A) of which
25 lL was used for ultra performance liquid chromatog-
raphy (UPLC) analysis. An AAP solution with a specific
radioactivity of 4,100 Bq [14C]AAP/100 lg AAP in blank
pooled plasma was used to prepare eight calibrators levels
and three quality control (QC) sample levels from 0.4 to
180 mBq/mL, and from 1.7 to 131 mBq/mL, respectively.
Calibrators (duplicate), QCs (triplicate), and sample
extracts were injected onto a UPLC coupled to a photodi-
ode array (PDA). Chromatographic conditions can be
found in Table 1. AAP in 100 % methanol was added to
each collected fraction to increase the carbon-12 content to
25 lg.
2.7.2 Accelerator Mass Spectrometry Analysis
[14C]AAP and metabolites were determined as described
recently [22]. A novel AMS sample introduction method
was used in this study to allow the routine analysis of
biomedical samples. The method consists of an automated
carbon dioxide (CO2) combustion device online coupled to
an AMS. Briefly, dried fractionated samples are placed in a
tin-foil cup and subsequently combusted using an ele-
mental analyzer (EA) (Vario Micro, Elementar, Germany).
The resulting CO2 was captured on a zeolyte trap at the
interface, connecting the EA to the AMS. CO2 was
released by heating of the trap and transferred to a vacuum
syringe using helium. The resulting 6 % v/v gas mixture of
CO2 with helium was infused at a pressure of 1 bar at
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60 lL/min into the titanium target in the SO110 ion source
of a 1 MV Tandetron AMS (High Voltage Engineering
Europe B.V., Amersfoort, The Netherlands) [23]. Within
the source, CO2 is converted into negative carbon ions. The
validation for the liquid chromatography (LC) ? AMS
analysis was based on the recommendation of the European
Bioanalytical Forum. Three QC concentration levels were
included: QC High 145 mBq/mL, QC Medium 14.5 mBq/
mL, and QC Low 2.4 mBq/mL. The accuracy of QC High,
Medium, and Low analysis corresponded to 104, 103, and
90 %, respectively. The precisions, defined by a coefficient
of variation, were 9.1, 6.7, and 6.9 %, respectively. All
values are well within the requirements for LC ? AMS
analysis [24]. The LLOQ of the method was 0.58 mBq/mL.
2.8 Data Analysis
Data were summarized as median (range), unless noted
otherwise. The plasma [14C]AAP and metabolite concen-
trations were calculated by converting measured Bq/L to
ng/L based on the dose given (3.3 ng/kg contained 60 Bq/
kg) and for the metabolites corrected for molecular weight
([14C]AAP 151 g/mol, [14C]AAP-Glu 237 g/mol, and
[14C]AAP-4Sul 231 g/mol) To compare the disposition of
oral [14C]AAP microdose with the intravenous therapeutic
doses, the microdose concentrations were dose normalized
to 15 mg/kg by multiplying with 5 9 10E6.
3 Results
3.1 Patients
Between 13 January and 31 May 2014, 32 patients were
eligible. Nine patients were excluded for logistical reasons
and 13 for refusal of informed consent. Parents’ informed
consent was received for ten patients who were subse-
quently dosed according to the protocol. One patient
vomited within 15 min post-dose and was excluded from
pharmacokinetic analysis. Table 2 provides a summary of
patient characteristics.
3.2 Detection of [14C]AAP and Metabolites in Plasma
Time profiles of [14C]AAP, [14C]AAP-Glu, and [14C]AAP-
4Sul metabolite plasma concentrations of two representa-
tive patients are shown in Fig. 1. These patients were
chosen as they represent the youngest and the oldest age
group. The Electronic Supplementary Material shows
graphs of all patients. The median time to maximum con-
centration (tmax) and maximum concentration (Cmax)
median (range) for [14C]AAP were, respectively, 153 min
(10–245 min) and 1.68 ng/L (0.75–4.76 ng/L), for
[14C]AAP-Glu were 248 min (161–382 min) and 0.88 ng/L
(0.34–1.55 ng/L), and for [14C]AAP-4Sul were 193 min
(115–343 min) and 0.81 ng/L (0.29–2.10 ng/L). Sample
collections were not complete for all patients as the arterial
line was prematurely removed or access to the line was
restricted for clinical reasons.
3.3 Dose-Normalized [14C]AAP and AAP Disposition
Semilog plots of the same two patients of dose-normalized
3.3 ng/kg oral [14C]AAP and 15 mg/kg every 6 h intrave-
nous AAP concentrations are shown in Fig. 2. Individual
graphs of all patients are displayed in the Electronic Sup-
plementary Material. Dose-normalized median [14C]AAP
Cmax concentrations approached median intravenous aver-
age concentrations (Cav) [median (range)]: 8.41 mg/L
(3.75–23.78 mg/L) and 8.87 mg/L (3.45–12.9 mg/L),
respectively.
4 Discussion
This proof-of-concept study shows the practical and ethical
feasibility of a [14C]microdose study in children to study
developmental pharmacokinetics.
Table 1 Ultra performance liquid chromatography conditions for
paracetamol (acetaminophen)
Eluent A 10 mM ammonium phosphate pH 3.4
Eluent B 100 % v/v methanol
UPLC column
(Waters Acquity)
BEH C18 1.7 lm 2.1 9 100 mm column
Flowrate 0.3 mL/min
Column temperature 30 C
Pressure 700 bar
Chromatography
conditions
0–1 min 100 % A and 0 % B
1–10 min linear gradient from 100 % A
and 0 % B to 95 % A and 5 % B
10–12 min 95 % A and 5 % B
12–15 min linear gradient from 95 % A
and 5 % B to 0 % A and 100 % B
15–20 min 0 % A and 100 % B
20–20.10 min linear gradient from 0 % A
and 100 % B to 100 % A and 0 % B
20.10–20.50 min 100 %A and 0 % B
20.50–28 min 100 % A and 0 % B at a
flowrate of 0.4 mL/min
28–29 min 100 % A and 0 % B
Collected fractions [14C]AAP-Glu (3.8–5.3 min)
[14C]AAP-4Sul (6.1–7.9 min)
[14C]AAP (8.1–9.8 min)
UPLC ultra performance liquid chromatography
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The concentrations of [14C]AAP are in the expected
range, when compared with dose-normalized concentra-
tions previously reported in neonates and children [25–27].
The average [14C]AAP concentrations and metabolite Cmax
values are also similar to those in a previous adult study:
1.64 versus 1.68 ng/mL for [14C]AAP, 0.88 versus 0.92 ng/
mL for [14C]AAP-Glu, and 0.62 versus 0.88 ng/mL for
[14C]AAP-4Sul [18]. The apparent lack of an age-related
difference in metabolite disposition is easily explained by
our small sample size and the even smaller number of
neonates in our cohort. This is supported by our observa-
tion that in the 4-day-old neonate [14C]AAP-4Sul concen-
trations are much higher than the [14C]AAP-Glu
concentrations, while the opposite is observed in the 2.4-
year-old, in line with developmental changes in AAP
metabolism. In the follow-up study up to 50 additional
patients will be included to study developmental changes in
AAP disposition with enough statistical power. Interest-
ingly, the average tmax values in our patients are much later
than in the adult study: 0.25 versus 2.6 h for [14C]AAP,
0.25 versus 4 h for [14C]AAP-Glu, and 0.5 versus 3.2 h for
[14C]AAP-4Sul. A possible explanation for this finding
may be slower oral absorption due to maturation and the
underlying critical illness or post-operative state in our
patients [26, 28].
The major barrier to a [14C]microdosing study in chil-
dren has been the perceived risk of radiation in the context
of a non-therapeutic trial [29, 30]. Still, radiation exposure
in this study was extremely low (\1 lSv), much lower than
yearly background exposure (2.5 mSv/year in The Neth-
erlands), a continental flight ([4 lSv), exposure from chest
X-ray (10 lSv), or computed tomography scans (100 lSv)
[7, 14]. To overcome parental ethical barriers to the study,
we added a letter from the Dutch collaborative patients’
organization for rare and genetic diseases (VSOP) to the
patient information leaflet, explaining the need for pediat-
ric drug research and the minimal risk involved in this
study. Surprisingly, from the informed consent conversa-
tions it appeared that most parents perceived there was
minimal risk involved. Fear for harmful radiation exposure
was not the main reason to deny informed consent. Parents
of the other children refused informed consent for reasons
relating to the burden of additional procedures and/or blood
sampling.
Table 2 Patient characteristics
Patient Post-natal age
(months)
Sex Primary diagnosis Intervention
1 3.6 Male Post-necrotizing enterocolitis sigmoı¨d
stenosis
Post-operative partial proximal colon resection
2 10.6 Female Scaphocephaly Post-operative craniofacial correction
3 1.7 Female Congenital cystic adenomatoid
malformation of the lung
Post-operative partial lung resection
4 0.3 Male Congenital diaphragmatic hernia Post-operative hernia correction
5 53.8 Male Scaphocephaly Post-operative craniofacial correction
6 28.9 Male Germ cell tumor Respiratory insufficiency due to mediastinal pressure
7a 83.1 Male Increased intracranial pressure Post-operative craniofacial correction
8 0.1 Male Congenital cardiac disease Monitoring respiratory insufficiency
9 6.2 Male Scaphocephaly Post-operative craniofacial correction
10 5.6 Male Duodenal web Post-operative duodenoduodenostomy and placing
gastrostomy tube
a Patient 7 excluded from results after vomiting within 15 min after microdose intake
Fig. 1 [14C]AAP and
metabolite plasma
concentrations after an oral
[14C]AAP 3.3 ng/kg dose
(lower limit of quantification
0.03 ng/L). AAP acetaminophen
(paracetamol), Glu glucuronide,
Sul sulphate
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Very sensitive LC–tandem mass spectrometry (LC-MS/
MS) techniques to measure the pharmacokinetics of an
unlabeled microdose may be an alternative to using a
radiolabeled microdose in general [31]. Nevertheless,
while low drug concentrations can be measured with LC-
MS/MS, this analytical method has not reached the very
low limits of detection of AMS. Hence, a larger unlabeled
dose may be needed, which may increase the risk of a
therapeutic or toxic effect [13]. Moreover, the use of an
unlabeled microdose would also prohibit the separation of
the disposition of an oral and intravenous dose given at the
same time. This could be overcome by using stable iso-
tope-labeled probe drugs, which have successfully been
used to study oral bioavailability using 15N3-midazolam in
adults [32]. This method also has the important disadvan-
tage that a much higher labeled drug dose is needed with
similar or even higher risk of therapeutic or toxic effect.
5 Conclusion
We have shown proof of concept for the practical and
ethical feasibility of a [14C]labeled microdose to study
pharmacokinetics in young children. This approach offers
innovative possibilities to perform phase I first-in-child
studies, especially for drugs with a small therapeutic win-
dow and high toxicity. In addition, it enables studies in
vulnerable populations such as critically ill neonates and
studies on developmental pharmacokinetics using probe
drugs for specific elimination pathways such as drug-
metabolizing enzymes and renal excretion.
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